Clinical Pharmacology and Drug Toxicity Practice Questions

Q: What is the percentage of tetracaine commonly used in cataract surgery?

0.5%. ***0.5%*** - A **0.5% concentration** of tetracaine is commonly used as a **topical anesthetic** in cataract surgery. - This concentration provides sufficient surface anesthesia for procedures without causing excessive corneal toxicity. *1%* - While 1% tetracaine can be used, it is generally considered a **higher concentration** than typically needed for routine cataract surgery. - Higher concentrations may increase the risk of **corneal epithelial toxicity** and delayed wound healing. *2%* - A 2% concentration of tetracaine is **rarely used** for topical anesthesia in cataract surgery due to its significantly increased risk of **corneal toxicity** and damage. - Such high concentrations are typically reserved for more intense, short-duration anesthetic needs, not routine ophthalmic procedures. *4%* - A 4% concentration of tetracaine is **not typically used** as a topical anesthetic for cataract surgery due to the very high risk of **significant corneal damage** and adverse effects. - This concentration would be **excessively potent** and harmful to the delicate ocular surface.

Q: What are the common side effects of the influenza vaccine?

All of the options. ***All of the options*** - The influenza vaccine commonly causes both **local and systemic side effects** as part of the body's normal immune response to vaccination. - All three listed side effects are well-documented common reactions that typically resolve within 1-2 days. **Local Reactions at Injection Site:** - **Soreness, pain, redness, and swelling** occur in 10-64% of vaccine recipients, representing the most common adverse effects. - **Itching** at the injection site is also frequently reported as part of the local inflammatory response. - These reactions indicate the immune system is responding appropriately to the vaccine antigens. **Systemic Reactions:** - **Fever** occurs in 10-40% of recipients (more common in children than adults), usually mild and lasting 1-2 days. - May be accompanied by other systemic symptoms like **myalgia, headache, and malaise**. - These represent the body's systemic immune response to the vaccine. **Clinical Significance:** - All these side effects are **expected, mild, and self-limiting** reactions. - They do not indicate vaccine failure or serious adverse events. - Patients should be counseled that these reactions are normal and typically resolve without intervention.

Q: What are the potential effects of amphetamine use during pregnancy?

All of the options. ***All of the options*** - Amphetamine use during pregnancy is associated with a wide range of adverse outcomes due to its **vasoconstrictive** and **teratogenic** effects. - This includes increased risks of **intrauterine growth restriction (IUGR)**, **cardiac anomalies**, and **cleft lip/palate**. *Intrauterine growth restriction (IUGR)* - Amphetamines cause **vasoconstriction**, which can reduce blood flow to the placenta and fetus, leading to **poor nutrient and oxygen delivery** and subsequent IUGR. - While IUGR is a significant risk, it is not the sole potential effect of amphetamine exposure. *Cardiac anomalies* - Amphetamines can disrupt early fetal development, specifically leading to an increased incidence of various **congenital heart defects**. - These cardiac malformations are just one component of the broader spectrum of anomalies associated with amphetamine exposure. *Cleft lip* - Maternal amphetamine use is linked to **craniofacial malformations**, including **cleft lip** and **cleft palate**, likely due to the drug's impact on neural crest cell migration and development. - This specific birth defect is among several potential structural abnormalities that can occur.

Q: Methysergide is banned due to which serious side effect?

Pulmonary fibrosis. ***Pulmonary fibrosis*** - Methysergide is a **serotonin antagonist** (specifically 5-HT₂) that was banned due to **serious fibrotic reactions**, which can affect multiple sites including the pleura, lungs, retroperitoneum, and heart valves. - **Pleuropulmonary fibrosis** (retropleural fibrosis) can lead to **restrictive lung disease** with impaired respiratory function, presenting as progressive dyspnea and chest pain. - While **retroperitoneal fibrosis** is the most common fibrotic complication, the broader spectrum of **fibrotic reactions** including pulmonary involvement led to the drug's withdrawal from most markets. - This is a serious and potentially life-threatening side effect that typically develops after prolonged use (usually >6 months). *Pleural effusion* - While pleural effusion can occur as a **secondary manifestation** of the underlying pleuropulmonary fibrosis, it is not the primary pathology. - The **fibrotic changes** themselves (not just the effusion) are the critical concern that led to the ban. - An isolated pleural effusion without fibrosis would not explain the drug's withdrawal. *Syncope* - **Syncope** (fainting) is not a recognized serious side effect of methysergide and was not responsible for its market withdrawal. - The drug's safety profile is dominated by **fibrotic complications**, not cardiovascular events like syncope. *Myocarditis* - **Myocarditis** (inflammation of the heart muscle) is not associated with methysergide use. - The cardiac complication related to methysergide is **endocardial and valvular fibrosis**, not inflammatory myocarditis. - This represents another manifestation of the drug's fibrotic side effect profile.

Q: In cases of poisoning, which substance is most effectively treated with alkaline diuresis?

Barbiturates. Correct: Barbiturates - **Alkaline diuresis** is highly effective for barbiturate poisoning because barbiturates are **weak acids** (pKa 7.2-8.5). - By alkalizing the urine (e.g., with **sodium bicarbonate** to pH 7.5-8.0), the drug becomes **ionized**, preventing its reabsorption in the renal tubules and promoting urinary excretion. - This is particularly effective for **long-acting barbiturates** like phenobarbital. *Incorrect: Benzodiazepine* - Benzodiazepines are generally **lipid-soluble** compounds and are extensively metabolized in the liver, primarily via **oxidation and glucuronidation**. - **Alkaline diuresis** is not an effective method for enhancing their elimination from the body. - The specific antidote is **flumazenil**, and treatment is primarily supportive [1]. *Incorrect: Dhatura* - **Dhatura poisoning** is caused by anticholinergic compounds (e.g., atropine, scopolamine) producing an anticholinergic toxidrome. - Management focuses on supportive care and the administration of **physostigmine** for severe anticholinergic symptoms. - **Alkaline diuresis** is not indicated for anticholinergic toxicity. *Incorrect: Morphine* - **Morphine** is an **opioid** that is primarily metabolized in the liver and excreted as glucuronide conjugates. - The specific antidote is **naloxone**, and treatment is primarily supportive. - **Alkaline diuresis** is not effective for enhancing morphine elimination, as opioids are not weak acids amenable to ion trapping.

Q: Which is the preferred antidote for methanol poisoning?

Fomepizole. ***Fomepizole*** - **Fomepizole** is a competitive inhibitor of **alcohol dehydrogenase**, the enzyme responsible for metabolizing methanol into toxic metabolites like formic acid. - By inhibiting this enzyme, it prevents the formation of toxic metabolites, thus reducing organ damage and metabolic acidosis. - **Fomepizole is the preferred first-line antidote** due to its easier dosing, absence of central nervous system depression, and less frequent monitoring requirements compared to ethanol. *Ethanol* - **Ethanol** also acts as a competitive inhibitor of **alcohol dehydrogenase**, similar to fomepizole, and is an effective alternative antidote. - However, it is now considered a **second-line option** when fomepizole is unavailable due to its disadvantages: difficult dosing requirements, CNS depression, need for frequent monitoring, and hypoglycemia risk. *Naloxone* - **Naloxone** is a specific opioid receptor antagonist used to reverse opioid overdose. - It has no role in the metabolism or detoxification of methanol poisoning. *Flumazenil* - **Flumazenil** is a benzodiazepine receptor antagonist used to reverse the effects of benzodiazepine overdose. - It does not have any therapeutic effect in cases of methanol poisoning.

Q: Neuropsychiatric symptoms are seen with which anti-tuberculosis drug?

Isoniazid (INH). ***Isoniazid (INH)*** - **Isoniazid** can cause **neuropsychiatric symptoms** due to its interference with **pyridoxine (vitamin B6)** metabolism, leading to a deficiency. - This deficiency can result in **peripheral neuropathy**, **optic neuritis**, seizures, psychosis, and cognitive impairment. *Rifampicin* - **Rifampicin** is associated with side effects such as **hepatotoxicity**, gastrointestinal disturbances, and a characteristic **orange discoloration of body fluids**. - It primarily affects the liver and GI tract but does not typically cause significant **neuropsychiatric symptoms**. *Pyrazinamide* - **Pyrazinamide** is known for causing **hyperuricemia** (leading to gouty arthritis) and **hepatotoxicity**. - While it can cause some central nervous system effects like headache, it is **not commonly associated with a broad range of neuropsychiatric symptoms** like INH. *Streptomycin* - **Streptomycin** is an aminoglycoside antibiotic primarily associated with **ototoxicity** (vestibular and auditory dysfunction) and **nephrotoxicity**. - Its side effect profile does not typically include **neuropsychiatric symptoms** as a prominent feature.

Q: A patient with recurrent gout attacks was started on a drug that inhibits uric acid synthesis. His symptoms were reduced after therapy. Which drug was he started on?

Allopurinol. ***Allopurinol*** - **Allopurinol** is a **xanthine oxidase inhibitor** that effectively reduces uric acid synthesis by blocking the enzyme responsible for converting hypoxanthine and xanthine to uric acid. - It is a cornerstone therapy for preventing recurrent gout attacks in patients with **hyperuricemia**. *Probenecid* - **Probenecid** is a **uricosuric agent** that increases the excretion of uric acid in the urine, rather than inhibiting its synthesis. - It works by inhibiting the reabsorption of uric acid in the renal tubules. *Colchicine* - **Colchicine** is an **anti-inflammatory agent** primarily used to treat acute gout flares and prevent future attacks by disrupting microtubule function and inhibiting neutrophil migration. - It does not affect uric acid synthesis or excretion. *Diclofenac* - **Diclofenac** is a **non-steroidal anti-inflammatory drug (NSAID)** used to manage the pain and inflammation associated with acute gout attacks. - It works by inhibiting prostaglandin synthesis and has no effect on uric acid levels.

Q: A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?

80 hours. ***80 hours (2 half-lives)***- Current digoxin level is **4 ng/mL**, which is **twice the upper therapeutic limit** (2 ng/mL), causing toxicity with nausea and vomiting [1]- After **1 half-life (40 hours)**: concentration reduces to 2 ng/mL (upper therapeutic limit) [2]- After **2 half-lives (80 hours)**: concentration reduces to 1 ng/mL (mid-therapeutic range) [2]- **Clinical rationale**: While 2 ng/mL is technically within range, waiting for 2 half-lives ensures the level is comfortably in the **middle of the therapeutic window** (1 ng/mL), providing a **safer margin** before resuming treatment in a patient who just experienced toxicity- This conservative approach minimizes risk of recurrent toxicity, especially important given the patient's recent symptoms at 4 ng/mL*1 half-life (40 hours)*- After 1 half-life, digoxin level would be 2 ng/mL, which is at the **upper limit** of the therapeutic range- While technically within the therapeutic range, this leaves **minimal safety margin** in a patient who just experienced toxicity- Starting treatment immediately at this level carries higher risk of recurrent side effects*120 hours (3 half-lives)*- After 3 half-lives, the concentration would be **0.5 ng/mL**, which is **below the therapeutic range** (1-2 ng/mL)- This is overly conservative and would **unnecessarily delay** resumption of essential cardiac medication- Could lead to inadequate control of the underlying condition (heart failure or atrial fibrillation)*140-180 hours (3.5-4.5 half-lives)*- This would reduce digoxin to **0.25-0.35 ng/mL**, well below therapeutic levels- This **excessive delay** is not clinically justified and could worsen the patient's cardiac condition- No standard protocol recommends waiting this long before resuming digoxin therapy

Q: A patient comes to the casualty with organophosphate poisoning. He was started on atropine infusion and pralidoxime. After 2 hours, the patient had a sudden rise in temperature. What is the most likely cause of the fever?

Fever due to atropine toxicity.. ***Fever due to atropine toxicity.*** - **Atropine** blocks muscarinic receptors, leading to inhibition of **sweat glands** and subsequent rise in body temperature (hyperthermia), especially with high doses or prolonged infusion. - Given the patient is receiving an **atropine infusion** and developed fever, **atropine toxicity** is a primary concern. *Side effect of pralidoxime.* - While pralidoxime can cause side effects like dizziness, blurred vision, or tachycardia, **fever is not a typical side effect** of pralidoxime. - Pralidoxime works by **regenerating acetylcholinesterase** [2, 3] and does not directly interfere with thermoregulation in a way that would cause fever. *Result of organophosphate poisoning.* - **Organophosphate poisoning** typically causes **hypothermia** due to excessive cholinergic stimulation leading to peripheral vasodilation and increased sweating [1]. - **Fever** is not a direct result of the acute phase of organophosphate poisoning itself, but rather a complication of treatment or other factors. *Unrelated or unknown cause.* - While possible, it's less likely to be "unrelated or unknown" when a clear pharmacological explanation (**atropine toxicity**) exists for fever in the context of the patient's treatment. - It would be important to first rule out known causes related to the ongoing treatment before attributing it to an unknown cause.

Question 1

What is the percentage of tetracaine commonly used in cataract surgery?

Accepted Answer

0.5%

Answer

1%

Answer

2%

Answer

4%

Question 2

What are the common side effects of the influenza vaccine?

Accepted Answer

All of the options

Answer

Fever after vaccination

Answer

Itching at the injection site

Answer

Local swelling at the injection site

Question 3

What are the potential effects of amphetamine use during pregnancy?

Accepted Answer

All of the options

Answer

Intrauterine growth restriction (IUGR)

Answer

Cardiac anomalies

Answer

Cleft lip

Question 4

Methysergide is banned due to which serious side effect?

Accepted Answer

Pulmonary fibrosis

Answer

Syncope

Answer

Pleural effusion

Answer

Myocarditis

Question 5

In cases of poisoning, which substance is most effectively treated with alkaline diuresis?

Accepted Answer

Barbiturates

Answer

Benzodiazepine

Answer

Dhatura

Answer

Morphine

Question 6

Which is the preferred antidote for methanol poisoning?

Accepted Answer

Fomepizole

Answer

Flumazenil

Answer

Naloxone

Answer

Ethanol

Question 7

Neuropsychiatric symptoms are seen with which anti-tuberculosis drug?

Accepted Answer

Isoniazid (INH)

Answer

Rifampicin

Answer

Pyrazinamide

Answer

Streptomycin

Question 8

A patient with recurrent gout attacks was started on a drug that inhibits uric acid synthesis. His symptoms were reduced after therapy. Which drug was he started on?

Accepted Answer

Allopurinol

Answer

Probenecid

Answer

Colchicine

Answer

Diclofenac

Question 9

A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?

Accepted Answer

80 hours

Answer

120 hours

Answer

140-180 hours

Answer

1 half-life (40 hours)

Question 10

A patient comes to the casualty with organophosphate poisoning. He was started on atropine infusion and pralidoxime. After 2 hours, the patient had a sudden rise in temperature. What is the most likely cause of the fever?

Accepted Answer

Fever due to atropine toxicity.

Answer

Side effect of pralidoxime.

Answer

Result of organophosphate poisoning.

Answer

Unrelated or unknown cause.

Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity — MCQs

On this page

Practice by Chapter

Want unlimited practice?